July 8, 2019 09:32 AM EDT

Medicxi, Taiho infuse €30M into Evotec spinout — eyeing cancer meds targeting DNA damage response pathways

Amber Tong

Betting on DNA damage response as the next big frontier in cancer therapies, Evotec is spinning out some of its discovery-stage work and drug targets …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Medicxi, Taiho infuse €30M into Evotec spinout — eyeing cancer meds targeting DNA damage response pathways

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Vertex makes money from sickle cell therapy Casgevy

Sana narrows focus again to zero in on diabetes and autoimmune disease

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Medicxi, Tai­ho in­fuse €30M in­to Evotec spin­out — eye­ing can­cer meds tar­get­ing DNA dam­age re­sponse path­ways

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Medicxi, Taiho infuse €30M into Evotec spinout — eyeing cancer meds targeting DNA damage response pathways